Fox Run Management L.L.C. Buys 18,575 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Fox Run Management L.L.C. raised its position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 96.4% during the 4th quarter, HoldingsChannel.com reports. The fund owned 37,838 shares of the company’s stock after acquiring an additional 18,575 shares during the period. Fox Run Management L.L.C.’s holdings in iTeos Therapeutics were worth $291,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of ITOS. KLP Kapitalforvaltning AS purchased a new position in shares of iTeos Therapeutics in the 4th quarter valued at approximately $299,000. American Century Companies Inc. grew its stake in iTeos Therapeutics by 7.5% in the fourth quarter. American Century Companies Inc. now owns 67,937 shares of the company’s stock worth $522,000 after purchasing an additional 4,727 shares during the period. Virtu Financial LLC raised its holdings in iTeos Therapeutics by 84.3% in the fourth quarter. Virtu Financial LLC now owns 18,493 shares of the company’s stock worth $142,000 after purchasing an additional 8,460 shares in the last quarter. AlphaQuest LLC lifted its position in iTeos Therapeutics by 274.9% during the fourth quarter. AlphaQuest LLC now owns 41,318 shares of the company’s stock valued at $317,000 after buying an additional 30,298 shares during the period. Finally, Raymond James Financial Inc. bought a new stake in shares of iTeos Therapeutics during the 4th quarter valued at $1,159,000. 97.16% of the stock is owned by institutional investors.

iTeos Therapeutics Stock Performance

Shares of ITOS stock opened at $6.70 on Friday. The company has a market capitalization of $255.90 million, a price-to-earnings ratio of -2.13 and a beta of 1.38. iTeos Therapeutics, Inc. has a one year low of $6.32 and a one year high of $18.75. The company’s 50-day moving average is $7.30 and its 200 day moving average is $8.51.

iTeos Therapeutics (NASDAQ:ITOS) last issued its earnings results on Wednesday, March 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.14) by $0.13. As a group, research analysts predict that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ITOS has been the subject of several research reports. JPMorgan Chase & Co. decreased their price target on shares of iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating for the company in a research note on Thursday, March 6th. Wedbush reaffirmed an “outperform” rating and set a $25.00 target price on shares of iTeos Therapeutics in a research note on Wednesday, March 5th. HC Wainwright reissued a “buy” rating and issued a $46.00 price target on shares of iTeos Therapeutics in a research report on Thursday, March 6th. Finally, Wells Fargo & Company cut their price target on iTeos Therapeutics from $19.00 to $17.00 and set an “overweight” rating on the stock in a research note on Thursday, March 6th.

iTeos Therapeutics Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.